Somewhat surprisingly, testing FLT3 inhibitors in ETP-ALL, where the frequency of FLT3-activating mutations is up to 35%, has progressed little since in vitro studies that demonstrated activity [38, 78]. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.